Literature DB >> 30393924

Subgroups of IBS patients are characterized by specific, reproducible profiles of GI and non-GI symptoms and report differences in healthcare utilization: A population-based study.

Annikka V Polster1, Olafur S Palsson2, Hans Törnblom1, Lena Öhman1,3, Ami D Sperber4, William E Whitehead2, Magnus Simrén1,2.   

Abstract

BACKGROUND: In a previous clinical sample of IBS patients, subgroups characterized by profiles of GI and non-GI symptoms were identified. We aimed to replicate these subgroups and symptom associations in participants fulfilling IBS diagnostic criteria from a population-based study and relate them to healthcare utilization.
METHODS: An Internet-based health survey was completed by general population adults from United States, Canada, and UK. Respondents fulfilling IBS diagnosis (Rome III and IV) were analyzed for latent subgroups using Gaussian mixture model analysis. Symptom measures were derived from validated questionnaires: IBS-related GI symptoms (Rome IV), extraintestinal somatic symptoms (PHQ-12), and psychological symptoms (SF-8). KEY
RESULTS: A total of 637 respondents fulfilled Rome III criteria (average age 46 years, range 18-87, 66% females) and 341 Rome IV criteria (average age 44, range 18-77, 64% female) for IBS. Seven subgroups were identified in the Rome III cohort, characterized by profiles of GI symptoms (constipation-related, diarrhea-related, and mixed, respectively), and further distinguished by the presence or absence of non-GI comorbidities. The Rome IV cohort showed five similar but less distinct subgroups with a preponderance of mixed symptom profiles. Higher severity of non-GI comorbidities was associated with more frequent healthcare visits and medication usage. CONCLUSIONS AND INFERENCES: In line with previous findings in a clinical IBS cohort, we were able to identify population-based subgroups characterized by a combination of GI symptoms with the additional distinction made by varying severity of non-GI symptoms and with differences in healthcare utilization.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  general population; irritable bowel syndrome; latent profile analysis; mixture model; subgrouping

Mesh:

Year:  2018        PMID: 30393924     DOI: 10.1111/nmo.13483

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  12 in total

1.  Gastrointestinal Symptoms in Women With Endometriosis and Microscopic Colitis in Comparison to Irritable Bowel Syndrome: A Cross-Sectional Study.

Authors:  Malin Ek; Bodil Roth; Mariette Bengtsson; Bodil Ohlsson
Journal:  Turk J Gastroenterol       Date:  2021-10       Impact factor: 1.852

Review 2.  Sex as a biological variable in irritable bowel syndrome.

Authors:  Michael Camilleri
Journal:  Neurogastroenterol Motil       Date:  2020-01-13       Impact factor: 3.598

3.  Characteristics and Risk Factors of Post-Infection Irritable Bowel Syndrome After Campylobacter Enteritis.

Authors:  Antonio Berumen; Ryan Lennon; Margaret Breen-Lyles; Jayne Griffith; Robin Patel; David Boxrud; Marijke Decuir; Gianrico Farrugia; Kirk Smith; Madhusudan Grover
Journal:  Clin Gastroenterol Hepatol       Date:  2020-07-23       Impact factor: 13.576

Review 4.  Impact of Diet on Symptoms of the Irritable Bowel Syndrome.

Authors:  Robin Spiller
Journal:  Nutrients       Date:  2021-02-09       Impact factor: 5.717

5.  Assessment of a 4-Week Starch- and Sucrose-Reduced Diet and Its Effects on Gastrointestinal Symptoms and Inflammatory Parameters among Patients with Irritable Bowel Syndrome.

Authors:  Clara Nilholm; Ewa Larsson; Emily Sonestedt; Bodil Roth; Bodil Ohlsson
Journal:  Nutrients       Date:  2021-01-28       Impact factor: 5.717

6.  A possible association between early life factors and burden of functional bowel symptoms in adulthood.

Authors:  Johanna Wennerberg; Shantanu Sharma; Peter M Nilsson; Bodil Ohlsson
Journal:  Scand J Prim Health Care       Date:  2021-11-22       Impact factor: 2.581

7.  Factors related to irritable bowel syndrome and differences among subtypes: A cross-sectional study in the UK Biobank.

Authors:  Kexin Wang; Huan Liu; Jingjing Liu; Liyuan Han; Zheng Kang; Libo Liang; Shengchao Jiang; Nan Meng; Peiwen Chen; Qiao Xu; Qunhong Wu; Yanhua Hao
Journal:  Front Pharmacol       Date:  2022-08-26       Impact factor: 5.988

8.  Epidemiologic Burden and Treatment of Chronic Symptomatic Functional Bowel Disorders in the United States: A Nationwide Analysis.

Authors:  Christopher Ma; Stephen E Congly; Kerri L Novak; Paul J Belletrutti; Maitreyi Raman; Matthew Woo; Christopher N Andrews; Yasmin Nasser
Journal:  Gastroenterology       Date:  2020-10-01       Impact factor: 22.682

9.  Altered Structural Covariance of Insula, Cerebellum and Prefrontal Cortex Is Associated with Somatic Symptom Levels in Irritable Bowel Syndrome (IBS).

Authors:  Cecilia Grinsvall; Lukas Van Oudenhove; Patrick Dupont; Hyo Jin Ryu; Maria Ljungberg; Jennifer S Labus; Hans Törnblom; Emeran A Mayer; Magnus Simrén
Journal:  Brain Sci       Date:  2021-11-29

10.  Extragastrointestinal Symptoms and Sensory Responses During Breath Tests Distinguish Patients With Functional Gastrointestinal Disorders.

Authors:  Clive H Wilder-Smith; Asbjørn M Drewes; Andrea Materna; Søren S Olesen
Journal:  Clin Transl Gastroenterol       Date:  2020-08       Impact factor: 4.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.